Prednisolone Sodium Phosphate – Amneal Pharmaceuticals
Amneal Pharmaceuticals manufactures a sterile injectable solution of prednisolone sodium phosphate. It is a water‑soluble, short‑acting glucocorticoid that is used when rapid onset of action is required (e.g., acute inflammation, allergic reactions, or in situations where oral therapy is impractical).
---
1. What Is Prednisolone Sodium Phosphate?
| Feature | Details |
|---|---|
| Generic name | Prednisolone sodium phosphate |
| Drug class | Synthetic glucocorticoid (corticosteroid) |
| Form | Sterile, preservative‑free injectable solution |
| Concentrations | 1 mg/mL (most common) or 5 mg/mL (higher‑strength option) |
| Packaging | 2 mL or 5 mL pre‑filled syringes, plus larger bulk ampoules for compounding |
| Manufacturer | Amneal Pharmaceuticals, Inc. |
---
2. How Is It Used?
| Indication | Typical Dose | Route | Notes |
|---|---|---|---|
| Acute inflammatory or allergic conditions (e.g., severe asthma attack, anaphylaxis, allergic bronchopulmonary aspergillosis) | 0.5–2 mg/kg IV (maximum 50 mg) | IV bolus or slow infusion | Use with caution in patients with uncontrolled diabetes or hypertension |
| Autoimmune or inflammatory disorders (e.g., rheumatoid arthritis flare, vasculitis) | 0.5–1 mg/kg IV or SC, often repeated 24–48 h apart | IV/SC | Often used as bridging therapy before transitioning to oral steroids |
| Eye inflammation (e.g., uveitis, postoperative inflammation) | 0.5–1 mg/mL ocular solution | Ophthalmic drops | Amneal offers a 1 mg/mL ophthalmic preparation |
| Pre‑operative anti‑inflammatory (e.g., in patients with severe airway inflammation) | 1–2 mg/kg IV 30–60 min pre‑op | IV | Reduces peri‑operative bronchospasm |
| Reversal of steroid‑induced hyperglycemia | 2–3 mg IV | IV | Sometimes given for severe hyperglycemia in ICU |
Important – The injectable form is not interchangeable with oral prednisolone or prednisone. Dosage calculations must account for the higher potency of the phosphate ester and the shorter half‑life.
---
3. How Is the Dose Calculated?
- Weight‑Based Dosing is most common in acute settings.
- Example: For a 70‑kg adult, 1 mg/kg = 70 mg IV (usually given as 10 mL of the 1 mg/mL solution).
- Maximum Daily Dose: Typically capped at 50–75 mg/day in most acute scenarios to reduce the risk of adrenal suppression.
- Tapering: After the initial IV course, patients are usually transitioned to a slow oral taper over 1–2 weeks depending on the underlying condition.
---
4. What Are the Common Side Effects?
| System | Common/Moderate | Severe/Uncommon |
|---|---|---|
| Metabolic | Hyperglycemia, fluid retention, hypertension | Severe hyperglycemia (especially in diabetics) |
| Immunologic | Increased infection risk, immunosuppression | Opportunistic infections (e.g., fungal, tuberculosis) |
| Endocrine | Adrenal suppression (short‑acting, usually reversible) | Cushingoid features if used >2 weeks |
| Gastrointestinal | Nausea, gastritis | GI bleeding (esp. with NSAID co‑therapy) |
| Neurological | Mood swings, insomnia | Psychosis (rare) |
| Musculoskeletal | Bone resorption, myopathy | Osteoporosis (long‑term) |
| Local (IV) | Phlebitis, irritation | Local tissue necrosis (rare) |
Tip: Patients with diabetes should have glucose monitored closely; patients with hypertension should monitor blood pressure. Those with a history of peptic ulcer disease may benefit from concurrent proton‑pump inhibitor therapy.
---
5. Contraindications & Precautions
| Category | Key Points |
|---|---|
| Absolute | Known hypersensitivity to prednisolone or any component of the formulation; untreated active infections (bacterial, fungal, viral) |
| Relative | Pregnancy (Category C; only if benefit > risk); lactation (prednisolone passes into breast milk); active systemic infection; uncontrolled diabetes; uncontrolled hypertension; severe osteoporosis; chronic use of high doses of other steroids |
| Caution | Use in elderly, patients with a history of GI ulcers, psychiatric disorders, or a weakened immune system. Always review concurrent medications for potential interactions. |
---
6. Drug Interactions
| Drug Class | Interaction | Clinical Impact |
|---|---|---|
| NSAIDs | ↑ GI irritation & bleeding | Consider proton‑pump inhibitor |
| Antidiabetic agents | ↑ glucose levels | May need dose adjustment |
| Anticoagulants | ↑ bleeding risk | Monitor coagulation status |
| Immunosuppressants | ↑ infection risk | Enhanced immunosuppression |
| Cytochrome‑P450 inhibitors (e.g., ketoconazole) | ↑ steroid metabolism inhibition | ↑ systemic exposure, risk of side effects |
| Corticosteroid‑metabolizing drugs | ↑ adrenal suppression | Avoid overlapping high‑dose steroids |
---
7. Storage & Handling
| Item | Details |
|---|---|
| Temperature | 2 °C – 8 °C (refrigerated) |
| Light | Store in original packaging; protect from light |
| Shelf Life | 24 months when refrigerated; 12 months at room temperature |
| Reconstitution | For bulk ampoules, sterile water for injection (S.W.I.) is used; for pre‑filled syringes, no reconstitution needed |
| Disposal | Follow